GSK Takes a Dive as Vaccine Sales Fall Short  

Stock GSK 02 adobe H00Vvg

The company reported a 72% decline in revenue from the RSV vaccine. Meanwhile, rival Pfizer said its RSV vaccine sales fell just 5%.

 

Leave a Reply